BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 27892716)

  • 1. Life and cancer without telomerase: ALT and other strategies for making sure ends (don't) meet.
    Apte MS; Cooper JP
    Crit Rev Biochem Mol Biol; 2017 Feb; 52(1):57-73. PubMed ID: 27892716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
    Gocha ARS; Harris J; Groden J
    Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere recombination and alternative telomere lengthening mechanisms.
    Draskovic I; Londono Vallejo A
    Front Biosci (Landmark Ed); 2013 Jan; 18(1):1-20. PubMed ID: 23276906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative Lengthening of Telomeres and Chromatin Status.
    Udroiu I; Sgura A
    Genes (Basel); 2019 Dec; 11(1):. PubMed ID: 31905921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin.
    Chan SW; Blackburn EH
    Oncogene; 2002 Jan; 21(4):553-63. PubMed ID: 11850780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative Lengthening of Telomeres Mediated by Mitotic DNA Synthesis Engages Break-Induced Replication Processes.
    Min J; Wright WE; Shay JW
    Mol Cell Biol; 2017 Oct; 37(20):. PubMed ID: 28760773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
    Zhao S; Wang F; Liu L
    Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
    Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
    PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative Lengthening of Telomeres is characterized by reduced compaction of telomeric chromatin.
    Episkopou H; Draskovic I; Van Beneden A; Tilman G; Mattiussi M; Gobin M; Arnoult N; Londoño-Vallejo A; Decottignies A
    Nucleic Acids Res; 2014 Apr; 42(7):4391-405. PubMed ID: 24500201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
    De Vitis M; Berardinelli F; Sgura A
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-telomeric recombination is present in telomerase-positive human cells.
    Dlaska M; Schöffski P; Bechter OE
    Cell Cycle; 2013 Jul; 12(13):2084-99. PubMed ID: 23759591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolving Roadblocks to Telomere Replication.
    Mason-Osann E; Gali H; Flynn RL
    Methods Mol Biol; 2019; 1999():31-57. PubMed ID: 31127568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative lengthening of telomeres can be maintained by preferential elongation of lagging strands.
    Min J; Wright WE; Shay JW
    Nucleic Acids Res; 2017 Mar; 45(5):2615-2628. PubMed ID: 28082393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells.
    Feng X; Luo Z; Jiang S; Li F; Han X; Hu Y; Wang D; Zhao Y; Ma W; Liu D; Huang J; Songyang Z
    J Cell Sci; 2013 Sep; 126(Pt 17):3982-9. PubMed ID: 23813958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative lengthening of telomeres in cancer stem cells in vivo.
    Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
    Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
    Pompili L; Leonetti C; Biroccio A; Salvati E
    J Exp Clin Cancer Res; 2017 Dec; 36(1):189. PubMed ID: 29273061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New twists to the ALTernative endings at telomeres.
    Bhargava R; Lynskey ML; O'Sullivan RJ
    DNA Repair (Amst); 2022 Jul; 115():103342. PubMed ID: 35588569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target.
    Pal J; Gold JS; Munshi NC; Shammas MA
    Transl Res; 2013 Dec; 162(6):364-70. PubMed ID: 24090770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NHP2 downregulation counteracts hTR-mediated activation of the DNA damage response at ALT telomeres.
    Raghunandan M; Geelen D; Majerova E; Decottignies A
    EMBO J; 2021 Mar; 40(6):e106336. PubMed ID: 33595114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative Lengthening of Telomeres in the Budding Yeast
    Cohn M; Andersson AK; Mateo RQ; Möller MC
    G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.